Double celebration for TopiVert and Sygnature Discovery as two drug candidates begin clinical trials

29th March 2017 – Nottingham and London, UK – One of Sygnature Discovery’s long-term clients, TopiVert Pharma, has recently initiated clinical trials with TOP1288 and TOP1630.  Both compounds were first synthesised at Sygnature during the successful collaboration.  TOP1288 and TOP1630 are Narrow Spectrum Kinase Inhibitors (NSKIs).  NSKIs target several important kinases in the signalling cascade […]

Keapstone Therapeutics and Sygnature Discovery collaborate to discover new therapies for Parkinson’s and Motor Neuron Disease

14th March 2017 – Sheffield, London and Nottingham, UK – Keapstone Therapeutics, a new biotech company formed by the University of Sheffield and Parkinson’s UK to develop new drugs for Parkinson’s and other neurodegenerative diseases, and Sygnature Discovery, the UK’s largest independent provider of integrated drug discovery resource and expertise, today announced they will collaborate […]

Sygnature has made the annual Sunday Times Lloyds SME Export Track 100 listing for the 3rd consecutive year due to the company’s increasing international client base

26th February 2017 – London, UK – The Sunday Times Lloyds SME Export Track 100 ranks Britain’s 100 small and medium-sized (SME) companies with the fastest-growing international sales over the latest two years. It is compiled by Fast Track and published in The Sunday Times each February. Sygnature Discovery has been listed in the SME Export Track […]

Sygnature Discovery, Mironid®, and Peak Proteins to collaborate to discover new therapies for life-threatening and currently incurable kidney disease, ADPKD

1st February 2017 – Nottingham, UK – Sygnature Discovery, Mironid® Limited, a leader in cell signalling-directed drug discovery and Peak Proteins, have announced they will work closely together to discover new therapies against diseases driven by elevated cyclic AMP (cAMP), such as Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a devastating, life-threatening and currently […]

Pelago Bioscience and Sygnature Discovery collaborate to Provide CETSA® based Target Engagement Assays

13th January 2017 – Nottingham, UK and Solna, Sweden – Sygnature Discovery today announced that it will collaborate with Pelago Bioscience, a Swedish biotech company to provide target engagement assays with Pelago’s patented Cellular Thermal Shift Assay (CETSA®) method. While target engagement has long been recognised as pivotal to targeted drug efficacy. Pelago’s CETSA method […]

Page 6 of 15« First...45678...Last »
Copyright © 2018 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.